John Libbey Eurotext

Hépato-Gastro & Oncologie Digestive

MENU

Primary small intestine neuroendocrine tumor resection with lymphadenectomy in patients with unresectable liver metastases: what we know about it? Volume 23, supplement 2, Octobre 2016

Figures

  • Figure 1
  • Figure 2
  • Figure 3

Tables

Authors
1 Hôpital Robert-Debré,
service de chirurgie générale,
digestive et endocrinienne,
avenue du Général-Koenig,
51026 Reims cedex, France
2 Hôpital Robert-Debré,
service d’hépato-gastroentérologie et de cancérologie digestive,
avenue du Général-Koenig,
51026 Reims cedex, France
3 Hôpital Maison Blanche,
service de radiologie,
avenue du Général-Koenig,
51026 Reims cedex, France
* Tirés à part

Unresectable liver metastases (LM) are present in one third of patient with small intestinal neuroendocrine tumour (siNET). The value of surgical resection for the primary tumor and mesenteric lymph nodes metastases in patients with unresectable metastatic disease is still a matter of debate. Retrospective studies suggest a possible benefit of resection of the primary tumor and mesenteric lymph nodes metastases in patients with unresectable LM, but those data have several limitations. While, the resection of symptomatic patients and patients with resectable LM is not debated, this is not the case in asymptomatic patients (unless carcinoid crisis) presenting with unresectable LM. We believe that the level of evidences is not high enough to let us propose it in selected patients, therefore a prospective randomised trial seems the best way to respond to this question.